CTD 第 2 部

2.7　臨床概要

2.7.5　参考文献

MSD 株式会社

2.7.5　参考文献

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 13]	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.	Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP.	Diabetes Obes. Metab. 2007; 9: 194-205.
[資料5.4: 14]	国際共同治験に関する基本的考え方（平成19年9月28日付、薬食審査発第0928010号）.	厚生労働省医薬食品局審査管理課長.	医薬品医療機器総合機構 [homepage on the Internet]. 2007 Sep 28 [cited 2014 Oct 8]. Available from: http://www.pmda.go.jp/operations/notice/2007/file/0928010.pdf.
[資料5.4: 15]	国際共同治験に関する基本的考え方（参考事例）（平成24年9月5日付、事務連絡）.	厚生労働省医薬食品局審査管理課.	医薬品医療機器総合機構 [homepage on the Internet]. 2012 Sep 5 [cited 2014 Oct 8]. Available from: http://www.pmda.go.jp/kijunsakusei/file/guideline/new_drug/GCT_jirei.pdf.
[資料5.4: 19]	Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.	Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al.	J Clin Endocrinol Metab. 2006; 91: 4612-9.
[資料5.4: 20]	Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.	Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, et al.	Curr Med Res Opin. 2009; 25: 2507-14.
[資料5.4: 21]	Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.	Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al	Ann Intern Med. 2006; 145: 247-54.
[資料5.4: 22]	糖尿病治療ガイド 2014-2015.	日本糖尿病学会.	文光堂 2014. p8-10, p13-14, p18-21, p24-25, p27-29.
[資料5.4: 23]	「経口血糖降下薬の臨床評価方法に関するガイドライン」について（薬食審査発0709第1号、平成22年7月9日）.	厚生労働省医薬食品局審査管理課長.	医薬品医療機器総合機構 [homepage on the Internet]. 2010 Jul 9 [cited 2014 Oct 8]. Available from: http://www.pmda.go.jp/kijunsakusei/file/guideline/new_drug/keikou-kettoukoukayaku-rinjyu-hyouka-guideline.pdf.

C Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 24]	The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.	The Diabetes Control and Complications Trial Research Group.	N Engl J Med. 1993; 329: 977-86.
[資料5.4: 25]	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.	Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al.	BMJ. 2000; 321: 405-12.
[資料5.4: 26]	Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria.	The DECODE study group.	Lancet. 1999; 354: 617-21.
[資料5.4: 27]	Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.	Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A.	Diabetes Care. 1999; 22: 920-4.
[資料5.4: 28]	Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program.	Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, et al.	Diabetes Care. 1999; 22: 1262-5.
[資料5.4: 29]	Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.	Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al.	Diabetologia. 1996; 39: 1577-83.
[資料5.4: 30]	Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study.	Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J.	Diabetes Care. 1997; 20: 163-9.
[資料5.4: 31]	Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.	Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T, et al.	Diabetes Care. 2003; 26: 868-74.
[資料5.4: 32]	DIABETES ATLAS. Sixth edition. 2013　Executive Summary.	International Diabetes Federation.	International Diabetes Federation [homepage on Internet]. 2013 [cited 2014 Sep 1]. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Exec_Sum_1.pdf.
[資料5.4: 33]	Longitudinal data analysis of continuous and discrete responses for pre-post designs.	Liang KY, Zeger SL.	Sankhyā: The Indian Journal of Statistics. 2000; 62: 134-48.

C Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 34]	Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.	Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, et al.	Int J Clin Pract. 2010; 64: 562-76.
[資料5.4: 35]	Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.	Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al.	Diabetes Obes Metab. 2010; 12: 442-51.
[資料5.4: 36]	Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.	Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K.	Diabetes Obes Metab. 2012; 14: 927-36.
[資料5.4: 37]	Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.	Seino Y, Hiroi S, Hirayama M, Kaku K.	J Diabetes Investig. 2012; 3: 517-25.
[資料5.4: 38]	Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.	Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, et al.	Diabetes Obes Metab. 2013; 15: 364-71.
[資料5.4: 39]	サキサグリプチン水和物審査報告書（平成25年2月26日）.	独立行政法人医薬品医療機器総合機構.	医薬品医療機器総合機構 [homepage on the Internet]. 2013 Feb 26 [cited 2014 Oct 10]. Available from: http://www.info.pmda.go.jp/shinyaku/P201300036/180078000_22500AMX00877_A100_2.pdf.
[資料5.4: 40]	Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients: effect of diet and physical activity.	Iwao T, Sakai K, Ando E.	Diabetol Int. 2013; 4: 173-8.
[資料5.4: 41]	Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients.	Sakura H, Tanaka Y, Iwamoto Y.	Diabetes Res Clin Pract. 2010; 88: 65-70.
[資料5.4: 42]	Seasonal variation in visceral fat and blood HbA1c in people with type 2 diabetes.	Iwata K, Iwasa M, Nakatani T, YanoY, Mifuji-Moroka R, Hara N, et al.	Diabetes Res Clin Pract. 2012; 96: e53-4.
[資料5.4: 43]	Seasonal changes in body composition and blood HbA1c levels without weight change in male patients with type 2 diabetes treated with insulin.	Sohmiya M, Kanazawa I, Kato Y.	Diabetes Care. 2004; 27: 1238-9.

C Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 44]	Seasonal variation of glycemic control in type 2 diabetic patients.	Ishii H, Suzuki H, Baba T, Nakamura K, Watanabe T.	Diabetes Care. 2001; 24: 1503.
[資料5.4: 45]	米国又は欧州添付文書（リナグリプチン、アログリプチン、サキサグリプチン、ビルダグリプチン、シタグリプチン） 2014年10月時点	各製造販売元.	－
[資料5.4: 46]	GLP-1-based strategies: a physiological analysis of differential mode of action.	Burcelin R, Gourdy P, Dalle S.	Physiology (Bethesda). 2014; 29: 108-21.
[資料5.4: 47]	Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.	Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide BM, Burton DD, et al.	Neurogastroenterol Motil. 2007; 19: 716-23.
[資料5.4: 48]	Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans.	Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA, et al.	Neuroimage. 2007; 35: 511-7.
[資料5.4: 49]	Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.	Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ.	Diabetes Ther. 2013; 4: 119-45.
[資料5.4: 50]	Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.	Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC.	Diabetes. 2013; 62: 2595-604.
[資料5.4: 51]	IHas pancreatic damage from glucagon suppressing diabetes drugs been underplayed?	Cohen D.	BMJ. 2013; 346: f3680.
[資料5.4: 52]	Pancreatic safety of incretin-based drugs--FDA and EMA assessment.	Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al.	N Engl J Med. 2014; 370: 794-7.
[資料5.4: 53]	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.	Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.	N Engl J Med. 2013; 369: 1317-26.
[資料5.4: 54]	Alogliptin after acute coronary syndrome in patients with type 2 diabetes.	White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.	N Engl J Med. 2013; 369: 1327-35.

Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 55]	Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.	Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al.	J Pharmacol Exp Ther. 2007; 321: 673-83.
[資料5.4: 56]	Scientific discussion vildagliptin. 2007.　Last updated July 2014.	EMEA.	—
[資料5.4: 57]	Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.	He H, Tran P, Yin H, Smith H, Flood D, Kramp R, et al.	Drug Metab Dispos. 2009; 37: 545-54.
[資料5.4: 58]	Saxagliptin FDA Approval Package: Clinical Pharmacology and Biopharmaceutics Review(s) (Application Number 22-350), 2009.	Center for Drug Evaluation and Research.	—
[資料5.4: 59]	Saxagliptin FDA Approval Package: Pharmacology Review(s) (Application Number 22-350), 2009.	Center for Drug Evaluation and Research.	—
[資料5.4: 60]	Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.	Lambeir AM, Durinx C, Scharpé S, De Meester I.	Crit Rev Clin Lab Sci. 2003; 40: 209-94.
[資料5.4: 61]	Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.	Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al.	Proc Natl Acad Sci U S A. 2000; 97: 6874-9.
[資料5.4: 62]	Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.	Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al.	Diabetes. 2005; 54: 2988-94.
[資料5.4: 63]	Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.	Vora KA, Porter G, Peng R, Cui Y, Pryor K, Eiermann G, et al.	BMC Immunol. 2009; 10: 19.
[資料5.4: 64]	Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding.	Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kähne T, Knott HM, et al.	Scand J Immunol. 2011; 73: 102-11.
[資料5.4: 65]	Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.	Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al.	Nature. 2013; 495: 251-4.

C Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 66]	TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.	Preller V, Gerber A, Wrenger S, Togni M, Marguet D, Tadje J, et al.	J Immunol. 2007; 178: 4632-40.
[資料5.4: 67]	CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model.	Kruschinski C, Skripuletz T, Bedoui S, Tschernig T, Pabst R, Nassenstein C, et al.	Clin Exp Immunol. 2005; 139: 17-24.
[資料5.4: 68]	Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.	Busso N, Wagtmann N, Herling C, Chobaz-Péclat V, Bischof-Delaloye A, So A, et al.	Am J Pathol. 2005; 166: 433-42.
[資料5.4: 69]	G1/S cell cycle arrest provoked in human T cells by antibody to CD26.	Ohnuma K, Ishii T, Iwata S, Hosono O, Kawasaki H, Uchiyama M, et al.	Immunology. 2002; 107: 325-33.
[資料5.4: 70]	Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.	Kim SJ, Nian C, McIntosh CH.	Diabetes. 2010; 59: 1739-50.
[資料5.4: 71]	Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.	Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, et al.	Endocrinology. 2010; 151: 3049-60.
[資料5.4: 72]	Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.	Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al.	Diabetes. 2011; 60: 1246-57.
[資料5.4: 73]	The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency.	Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS.	J Exp Med. 2000; 192: 1223-36.
[資料5.4: 74]	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.	Monami M, Dicembrini I, Martelli D, Mannucci E.	Curr Med Res Opin. 2011; 27 Suppl 3: 57-64.
[資料5.4: 75]	Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients.	Zannad F, Cannon C, Cushman W, Bakris G, Nissen S, Heller S, et al.	J Am Coll Cardiol. 2014; 63 (12) Suppl: A117.
[資料5.4: 76]	Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.	Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT.	JACC Heart Fail. 2014; doi: 10.1016/j.jchf.2014.04.005. [Epub ahead of print]

C Confidential

添付資料番号	タイトル	著者	掲載紙
[資料5.4: 77]	Diabetes and cancer.	Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R.	Endocr Relat Cancer. 2009; 16: 1103-23.
[資料5.4: 78]	Diabetes and cancer: a consensus report.	Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al.	Diabetes Care. 2010; 33: 1674-85.
[資料5.4: 79]	Report of the JDS/JCA joint committee on diabetes and cancer.	Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, Noto H, et al.	Diabetol Int. 2013; 4: 81-96.
[資料5.4: 80]	Charter for the Adjudication of Pancreatitis in the MK-3102 Program.	Merck Research Laboratories	社内資料
[資料5.4: 81]	Charter for the Adjudication of Hypersensitivity Reactions in the MK-3102 Program.	Merck Research Laboratories	社内資料
[資料5.4: 82]	Standard Operating Procedure for the Surveillance, Monitoring, and Adjudication of Serious Adverse Events of Vascular Events, Heart Failure Events and Deaths, and Revascularization Procedures, in Clinical Trials of MK-3102.	Merck Research Laboratories	社内資料
[資料5.4: 83]	Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.	DeFronzo RA.	Diabetes. 1988; 37: 667-87.

C Confidential